Today, the criteria for diagnosis and treatment have evolved into an evidence-based medicine approach. The need for evidence-based information is especially critical in the management of gestational diabetes, in general, and especially in the use of oral hypoglycemic agents. These agents have been categorically contraindicated for decades in the United States based on anecdotal and/or weak evidence for these recommendations. In this article, the similarities between gestational and type 2 diabetes are described and the rationale for the use of oral hypoglycemic agents for the treatment of both are discussed. The author will show how research from basic sciences (placental transfers) to clinical studies (perinatal outcome) can lead to significant evidence on which to base management recommendations.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1053/sper.2002.33960 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Deprescribing in Older Adults With Type 2 Diabetes: Associations With Patients' Perspectives: The Diabetes and Aging Study.
J Am Geriatr Soc
January 2025
Division of Research, Kaiser Permanente, Pleasanton, California, USA.
Background: Little is known about how patients' preferences, expectations, and beliefs (jointly referred to as perspectives) influence deprescribing. We evaluated the association of patients' self-reported perspectives with subsequent deprescribing of diabetes medications in older adults with type 2 diabetes.
Methods: Longitudinal cohort study of 1629 pharmacologically treated adults ages 65-100 years with type 2 diabetes who received care at Kaiser Permanente of Northern California (KPNC) and participated in the Diabetes Preferences and Self-Care survey (2019).
evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease.
Alzheimers Res Ther
January 2025
Alzheimer Center Amsterdam, Department of Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
Background: Disease-modifying therapies targeting the diverse pathophysiology of Alzheimer's disease (AD), including neuroinflammation, represent potentially important and novel approaches. The glucagon-like peptide-1 receptor agonist semaglutide is approved for the treatment of type 2 diabetes and obesity and has an established safety profile. Semaglutide may have a disease-modifying, neuroprotective effect in AD through multimodal mechanisms including neuroinflammatory, vascular, and other AD-related processes.
View Article and Find Full Text PDFhaploinsufficiency in a mother-daughter pair with young-onset diabetes with and without neonatal hypoglycemia.
Clin Pediatr Endocrinol
January 2025
Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo, Japan.
The ATP-binding cassette transporter subfamily C member 8 (ABCC8) regulates insulin secretion from β-cells. Loss- and gain-of-function variants of have been implicated in neonatal hyperinsulinemic hypoglycemia and young-onset diabetes, respectively. Although some patients with variants have been reported to exhibit both neonatal hypoglycemia and young-onset diabetes, the molecular and clinical characteristics of this atypical phenotype remain unknown.
View Article and Find Full Text PDFPreparation and Hypoglycemic Effect of Magnolia Officinalis Polysaccharide Oral Liquid.
Plant Foods Hum Nutr
January 2025
Hubei Key Laboratory of Biologic Resources Protection and Utilization, Hubei Minzu University, Enshi, 445000, P.R. China.
In this paper, an oral liquid containing Magnolia officinalis polysaccharide was formulated and its hypoglycemic effects were investigated. An orthogonal test was conducted based on single-factor experiments to optimize the formulation guided by sensory evaluations. Its stability and safety were also assessed.
View Article and Find Full Text PDFAnti-diabetic and anti-microbial activity of aspalathus linearis and syzygium aromaticum formulation mediated zinc oxide nanoparticles.
Med J Malaysia
January 2025
Nanobiomedicine lab, Centre for Global Health Research, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, Tamilnadu, India.
Introduction: Zinc oxide nanoparticles (ZnO NPs) exhibit a wide range of biomedical applications majorly used as antiinflammatory, anti-cancer, anti-diabetic, and anti-microbial activity and other biomedical applications because they show less toxicity and are very compatible. Zinc metal is an inorganic and essential element in the human body at the trace level. ZnO NPs are also GRAS substances (Generally Recognized As Safe).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!